Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.

Trial Profile

Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms IRMA
  • Most Recent Events

    • 06 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.
    • 06 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
    • 25 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top